交易 Scholar Rock Holding Corp - SRRK
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.最新股票文章

NVIDIA 股價預測:第三季財報與執行長交接
美國半導體巨頭 NVIDIA(NVDA)於 2026 年 11 月 17 日公布 2027 財年第三季營收達 1,158 億美元,年增 103%。深入了解第三方目標價與技術分析。過往表現並非未來結果的可靠指標。
3 小時前

台積電股價預測:第三方目標價
台灣積體電路製造公司(TSM)在2025年9月25日UTC下午4時55分報276.65美元,盤中區間介於270.91美元至282.95美元之間。
08:56, 3 11月 2026

IonQ 股價預測:第三方目標價
IonQ 開發囚禁離子量子系統,2026 年第一季調整後 EBITDA 虧損 9,680 萬美元,同時致力打造 256 量子位元系統。探索第三方 IONQ 目標價與技術分析。過往表現並非未來結果的可靠指標。
09:45, 30 10月 2026
